📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Artemis Medicare to Manage 650+ Bed VIMHANS Hospital; Plans ₹520 Cr CAPEX
Artemis Medicare has entered into a long-term Medical Services Agreement to operate and manage the VIMHANS hospital in South Delhi. The project involves a phased investment of ₹500-520 crore, with the first 450 beds expected to be operational by FY29. This strategic move targets a high-ARPOB (Average Revenue per Occupied Bed) micro-market and will nearly double the company's existing capacity of approximately 800 beds. The agreement spans an initial 15 years, extendable by another 15 years, significantly strengthening Artemis's footprint in the Delhi NCR healthcare sector.
Key Highlights
Addition of 650+ beds in prime South Delhi location, nearly doubling current ~800-bed capacity
Total planned CAPEX of ₹500-520 crore (₹75-80 lakh per bed) funded via internal accruals and debt
Phase 1 commissioning of 450 beds targeted for FY29, with subsequent expansion to 650+ beds
Long-term exclusive management rights for 15 years, extendable by another 15 years at company's option
Strategic focus on high-margin specialties including neurosciences, oncology, and robotic surgery
💼 Action for Investors
This expansion is a significant long-term growth driver in a high-demand market, though the FY29 operational timeline implies a long gestation period. Investors should monitor the company's debt levels and execution milestones over the next three years.
Delhi High Court Dismisses ₹3.92 Crore PF Dispute Against Artemis Medicare
Artemis Medicare Services Limited has successfully defended a legal challenge regarding a ₹3.92 crore provident fund demand. The Delhi High Court dismissed a writ petition filed by the Regional Provident Fund Commissioner that sought to overturn a previous favorable tribunal ruling. This decision confirms the setting aside of the original demand issued in January 2021. The resolution of this litigation removes a potential financial liability and legal overhang for the company.
Key Highlights
Delhi High Court dismissed the writ petition filed by the Regional Provident Fund Commissioner on January 28, 2026
The litigation concerned a demand for ₹3.92 crores in outstanding provident fund contributions
The ruling upholds a February 2023 decision by the Central Government Industrial Tribunal (CGIT) in favor of the company
The dismissal was based on jurisdictional grounds raised by Artemis Medicare
💼 Action for Investors
This is a positive outcome that clears a legal hurdle and a ₹3.92 crore contingent liability. Investors can remain confident in the company's ability to manage regulatory disputes effectively.
Artemis Medicare Q3 Revenue Up 17.2% to ₹272 Cr; Board Approves ₹700 Cr Fundraise for Expansion
Artemis Medicare reported a steady Q3 FY26 with revenue growing 17.2% YoY to ₹272 crores and PAT rising 7.9% to ₹22 crores. The company is entering a significant growth phase, aiming to triple its bed capacity from approximately 800 to 2,300 beds by 2029. This expansion is supported by a board-approved ₹700 crore fundraise and includes key projects in Raipur and South Delhi. Operational efficiency remains high with ARPOB increasing 10% to ₹84,100, bolstered by a 34.9% growth in high-margin international patient revenue.
Key Highlights
Q3 FY26 revenue grew 17.2% YoY to ₹272 Cr with an EBITDA margin of 19.1% for the quarter.
ARPOB increased 10% YoY to ₹84,100, driven by complex procedures and a 34% contribution from international patients.
Board approved a ₹700 Cr fundraise to scale capacity to 2,300 beds by 2029, up from the current ~800 beds.
300-bed Raipur hospital is scheduled for commissioning in April-May 2026, marking geographic diversification.
Platinum Green Building certification at Gurugram facility allows for 100-125 additional beds via a 15% FAR increase.
💼 Action for Investors
Investors should monitor the execution of the aggressive 2,300-bed expansion plan and the upcoming ₹700 Cr fundraise as these will be primary valuation drivers. The strong growth in international medical tourism and rising ARPOB suggest a healthy core business capable of funding future debt/equity requirements.
Artemis Medicare Q3 Revenue Up 17.2% to ₹272 Cr, International Patient Revenue Surges 34.9%
Artemis Medicare reported a steady Q3 FY26 with consolidated revenue growing 17.2% YoY to ₹27,235 Lacs. While quarterly PAT growth was modest at 7.9%, the 9-month consolidated PAT showed a robust increase of 23.9% YoY. Operational efficiency improved as Average Revenue Per Occupied Bed (ARPOB) rose to ₹84,100, supported by a 34.9% jump in high-margin international patient revenue. The company confirmed its Raipur facility expansion is on track for an April 2026 launch, providing a clear roadmap for future capacity growth.
Key Highlights
Consolidated Revenue from operations grew 17.2% YoY to ₹27,235 Lacs in Q3 FY26.
Average Revenue Per Occupied Bed (ARPOB) increased to ₹84,100 from ₹76,485 in the previous year.
International patient revenue grew by 34.9% YoY, contributing 34% to the total net revenue.
9-month consolidated PAT increased by 23.9% YoY to ₹7,343 Lacs.
Raipur facility development is on schedule with operations expected to commence in April 2026.
💼 Action for Investors
Investors should monitor the successful commissioning of the Raipur facility in April 2026 as a key growth driver. The strong growth in ARPOB and international medical tourism segments suggests improving margins and a favorable case mix.
Artemis Medicare Q3 FY26 Revenue Up 17% to ₹272 Cr; Proposes ₹700 Cr Fundraise
Artemis Medicare reported a steady Q3 FY26 with consolidated revenue growing 17.2% YoY to INR 272 Cr, driven by a 10% increase in ARPOB to INR 84,100. While PAT grew 7.9% to INR 22 Cr, margins saw a slight compression to 19.1% due to increased manpower costs for new specialized departments like Robotics and Geriatrics. The company is aggressively expanding its footprint, targeting 2,000 beds by 2028, and plans to raise INR 700 Cr to fund this growth. Operational performance at the flagship Gurgaon hospital remains strong with IP volumes up 13.3% YoY.
Key Highlights
Consolidated Revenue for Q3 FY26 grew 17.2% YoY to INR 27,235 Lacs.
ARPOB at Gurgaon facility increased by 10% YoY to INR 84,100 with occupancy at 62%.
Company proposes to raise ~INR 700 Cr to support its capital requirements and 2,000-bed target.
9M FY26 PAT showed robust growth of 23.9% YoY, reaching INR 7,343 Lacs.
Expansion on track with a 300+ bed Raipur hospital expected to be operational by April/May 2026.
💼 Action for Investors
Investors should focus on the successful commissioning of the Raipur facility and the terms of the proposed INR 700 Cr fundraise. The company remains a strong growth candidate in the healthcare space given its improving operational metrics and clear capacity expansion roadmap.
Artemis Medicare Q3 PAT Grows 8% to ₹22.5 Cr; Board Approves ₹700 Cr Fundraise
Artemis Medicare Services reported a steady performance for Q3 FY26, with revenue from operations increasing by 17.7% YoY to ₹267.12 crore. Net profit for the quarter rose 8.3% YoY to ₹22.51 crore, even after accounting for a ₹3.07 crore exceptional charge related to new Labour Codes. A major strategic highlight is the Board's approval to raise up to ₹700 crore through various instruments including QIP and preferential allotment. For the nine-month period ended December 2025, the company has shown robust growth with PAT increasing by 22.6% to ₹73.89 crore.
Key Highlights
Revenue from operations grew 17.7% YoY to ₹267.12 crore in Q3 FY26.
Net Profit for the quarter stood at ₹22.51 crore versus ₹20.78 crore in the previous year.
Board approved a massive fundraise of up to ₹700 crore via equity or convertible securities.
9M FY26 PAT increased significantly by 22.6% YoY to ₹73.89 crore.
Recognized an exceptional item of ₹3.07 crore due to the financial impact of new Labour Codes.
💼 Action for Investors
Investors should monitor the terms and pricing of the ₹700 crore fundraise as it indicates significant expansion plans, though it may lead to equity dilution. The consistent double-digit revenue growth suggests strong demand for the company's healthcare services.
Artemis Medicare Q3 Profit Up 8% to ₹22.5 Cr; Board Approves ₹700 Cr Fundraise
Artemis Medicare reported a steady performance for Q3 FY26, with revenue from operations growing 17.7% YoY to ₹267.12 crore. Net profit increased by 8.3% YoY to ₹22.51 crore, despite an exceptional charge of ₹3.07 crore related to the implementation of new Labour Codes. A major highlight is the Board's approval to raise up to ₹700 crore through various equity-linked instruments, signaling potential expansion or debt restructuring. International revenue remains a strong contributor, accounting for nearly 33% of the total quarterly revenue.
Key Highlights
Revenue from operations increased 17.7% YoY to ₹267.12 crore in Q3 FY26.
Net profit stood at ₹22.51 crore, up from ₹20.78 crore in the same quarter last year.
Board approved a massive fundraise of up to ₹700 crore via QIP, private placement, or other equity instruments.
International revenue grew to ₹87.50 crore, contributing 32.7% to the total revenue mix.
9M FY26 net profit reached ₹73.89 crore, a 22.6% increase over the ₹60.25 crore recorded in 9M FY25.
💼 Action for Investors
Investors should view the ₹700 crore fundraise approval as a significant catalyst for future growth and capacity expansion. The stock remains a 'Watch' to see the specific terms of the fundraise and how the capital will be deployed to enhance return ratios.